Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 18;20(22):1442-1446.
doi: 10.4244/EIJ-D-24-00158.

Temporal trends in characteristics of patients undergoing transcatheter tricuspid edge-to-edge repair for tricuspid regurgitation

Karl-Patrik Kresoja  1   2 , Lukas Stolz  3 , Anne Schöber  1   2 , KarlPhilipp Rommel  2 , Sebastian Rosch  1   2 , Florian Schlotter  2 , Muhammed Gerçek  4 , Christoph Pauschinger  5   6 , Wolfgang Rottbauer  7 , Mohammad Kassar  8 , Bjoern Goebel  9 , Paolo Denti  10 , Tienush Rassaf  11 , Manuel Barreiro-Perez  12 , Peter Boekstegers  13 , Monika Zdanyte  14 , Marianna Adamo  15 , Flavien Vincent  16 , Philipp Schlegel  17 , Ralph-Stephan von Bardeleben  1 , Mirjam G Wild  18 , Stefan Toggweiler  19 , Mathias H Konstandin  17 , Eric van Belle  16 , Marco Metra  15 , Tobias Geisler  14 , Rodrigo Estévez-Loureiro  12 , Peter Luedike  11 , Francesco Maisano  10 , Philipp Lauten  9 , Fabien Praz  8 , Mirjam Kessler  7 , Andreas Ruck  20 , Daniel Kalbacher  5   6 , Volker Rudolph  4 , Christos Iliadis  21 , Holger Thiele  3 , Jörg Hausleiter  3   22 , Philipp Lurz  1 , On Behalf Of The EuroTR Investigators
Affiliations

Temporal trends in characteristics of patients undergoing transcatheter tricuspid edge-to-edge repair for tricuspid regurgitation

Karl-Patrik Kresoja et al. EuroIntervention. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

K.-P. Kresoja reports travel expenses from Edwards Lifesciences. L. Stolz received speaker honoraria from Edwards Lifesciences. W. Rottbauer received speaker honoraria from Edwards Lifesciences and Abbott. P. Denti served as a consultant for InnovHeart, Pi-Cardia, HVR Cardio, and Approxima; and received speaker honoraria from Abbott and Edwards Lifesciences. T. Rassaf received speaker honoraria and consulting fees from AstraZeneca, Bayer, Pfizer, and Daiichi Sankyo. M. Barreiro-Perez received speaker fees from Abbott, Edwards Lifesciences, and Venus Medtech. M. Adamo has received consulting fees in the last three years from Abbott and Edwards Lifesciences. R.-S. von Bardeleben has received institutional grants and served as speaker to Abbott and Edwards Lifesciences. S. Toggweiler has received personal honoraria from Medtronic, Boston Scientific, Biosensors, Abbott, Medira, Shockwave Medical, Teleflex, atHeart Medical, Cardiac Dimensions, Polares Medical, Amarin, Sanofi, AstraZeneca, ReCor Medical, and Daiichi Sankyo; has received institutional research grants from Edwards Lifesciences, Boston Scientific, Fumedica, Novartis, and Boehringer Ingelheim; and holds equity in Hi-D Imaging. M. Metra has received consulting fees in the last three years from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Edwards Lifesciences, and Roche Diagnostics. T. Geisler received speaker honoraria/research grants from AstraZeneca, Bayer, Bristol-Myers Squibb/Pfizer, Ferrer/Chiesi, Medtronic, and Edwards Lifesciences, but none of these were related to this study. R. Estévez-Loureiro received speaker fees from Abbott, Edwards Lifesciences, Boston Scientific, and Venus Medtech. P. Luedike received speaker honoraria and consulting fees from AstraZeneca, Bayer, Pfizer, and Edwards Lifesciences; and research honoraria from Edwards Lifesciences. F. Maisano received grant and/or research institutional support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, NVT, Terumo, and Venus Medtech; consulting fees, honoraria personal and institutional from Abbott, Medtronic, Edwards Lifesciences, Xeltis, Cardiovalve, Occlufit, Simulands, Mtex, Venus Medtech, Squadra, and Valgen; royalty income/IP rights from Edwards Lifesciences; and is a shareholder (including share options) of Magenta, Transseptal Solutions, and 4Tech. F. Praz received travel expenses from Edwards Lifesciences, Abbott, Polares Medical, Medira, and Siemens Healthineers. M. Kessler received speaker honoraria from Edwards Lifesciences and Abbott. D. Kalbacher has received personal fees from Abbott, Edwards Lifesciences, and Pi-Cardia. V. Rudolph received research grants from Abbott, Boston Scientific, and Edwards Lifesciences. C. Iliadis received consultant fees and travel expenses from Abbott and Edwards Lifesciences. J. Hausleiter reports research grant support and speaker honoraria from Edwards Lifesciences. P. Lurz received institutional grants from Edwards Lifesciences and honoraria from Innoventric. The other authors have no relevant conflicts of interest to declare.

Similar articles

See all similar articles

References

    1. Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, Lurz P, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, Deuschl F, Estevez-Loureiro R, Fam N, Frerker C, Gavazzoni M, Hausleiter J, Ho E, Juliard JM, Kaple R, Besler C, Kodali S, Kreidel F, Kuck KH, Latib A, Lauten A, Monivas V, Mehr M, Muntané-Carol G, Nazif T, Nickening G, Pedrazzini G, Philippon F, Pozzoli A, Praz F, Puri R, Rodés-Cabau J, Schäfer U, Schofer J, Sievert H, Tang GHL, Thiele H, Topilsky Y, Rommel KP, Delgado V, Vahanian A, Von Bardeleben RS, Webb JG, Weber M, Windecker S, Winkel M, Zuber M, Leon MB, Hahn RT, Bax JJ, Enriquez-Sarano M, Maisano F. Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation. J Am Coll Cardiol. 2019;74:2998–3008. - PubMed
    1. Kresoja KP, Lauten A, Orban M, Rommel KP, Alushi B, Besler C, Braun D, Unterhuber M, Stangl K, Landmesser U, Massberg S, Thiele H, Hausleiter J, Lurz P. Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction. Eur J Heart Fail. 2020;22:1817–25. - PubMed
    1. Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, Price MJ, Singh G, Fam N, Kar S, Schwartz JG, Mehta S, Bae R, Sekaran N, Warner T, Makar M, Zorn G, Spinner EM, Trusty PM, Benza R, Jorde U, McCarthy P, Thourani V, Tang GHL, Hahn RT, Adams DH TRILUMINATE Pivotal Investigators. Transcatheter Repair for Patients with Tricuspid Regurgitation. N Engl J Med. 2023;388:1833–42. - PubMed
    1. Russo G, Badano LP, Adamo M, Alessandrini H, Andreas M, Braun D, Connelly KA, Denti P, Estevez-Loureiro R, Fam N, Gavazzoni M, Hahn RT, Harr C, Hausleiter J, Himbert D, Kalbacher D, Ho E, Latib A, Lubos E, Ludwig S, Lurz P, Monivas V, Nickenig G, Pedicino D, Pedrazzini G, Pozzoli A, Pires Marafon D, Pastorino R, Praz F, Rodes-Cabau J, Besler C, Schofer J, Scotti A, Piayda K, Sievert H, Tang GHL, Thiele H, Schlotter F, von Bardeleben RS, Webb J, Windecker S, Leon M, Maisano F, Metra M, Taramasso M. Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry. Eur J Heart Fail. 2023;25:2243–51. - PubMed
    1. Hahn RT, Lawlor MK, Davidson CJ, Badhwar V, Sannino A, Spitzer E, Lurz P, Lindman BR, Topilsky Y, Baron SJ, Chadderdon S, Khalique OK, Tang GHL, Taramasso M, Grayburn PA, Badano L, Leipsic J, Lindenfeld J, Windecker S, Vemulapalli S, Redfors B, Alu MC, Cohen DJ, Rodés-Cabau J, Ailawadi G, Mack M, Ben-Yehuda O, Leon MB, Hausleiter J TVARC Steering Committee. Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints. J Am Coll Cardiol. 2023;82:1711–35. - PubMed

LinkOut - more resources